Article(id=1210517367105385436, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1210517366081975259, articleNumber=null, orderNo=null, doi=10.16438/j.0513-4870.2022-0121, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=research-article, receivedDate=1643126400000, receivedDateStr=2022-01-26, revisedDate=1648137600000, revisedDateStr=2022-03-25, acceptedDate=null, acceptedDateStr=null, onlineDate=1766539430643, onlineDateStr=2025-12-24, pubDate=1668182400000, pubDateStr=2022-11-12, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1766539430643, onlineIssueDateStr=2025-12-24, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1766539430643, creator=13701087609, updateTime=1766539430643, updator=13701087609, issue=Issue{id=1210517366081975259, tenantId=1146029695717560320, journalId=1189982191388893191, year='2022', volume='57', issue='11', pageStart='3259', pageEnd='3450', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1766539430399, creator=13701087609, updateTime=1766539608198, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1210518111875363690, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1210517366081975259, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1210518111875363691, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1210517366081975259, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=3310, endPage=3315, ext={EN=ArticleExt(id=1210517368002966498, articleId=1210517367105385436, tenantId=1146029695717560320, journalId=1189982191388893191, language=EN, title=Preparation of anti-human TIGIT monoclonal antibody and preliminary study of its biological activity, columnId=1190335348761793317, journalTitle=Acta Pharmaceutica Sinica, columnName=Original Articles, runingTitle=null, highlight=null, articleAbstract=
T cell immune receptor with Ig and ITIM domains (TIGIT), a promising new target in cancer immunotherapy, plays a critical role in limiting adaptive and innate immunity against tumors. The extracellular domain of human TIGIT was used to immune BALB/c mice, and a new anti-human TIGIT chimeric antibody (c7D3) was developed. The mice in this study were used in accordance with the international guidelines for the care and use of laboratory animals, and the animal study was approved by the Institutional Animal Ethics Committee of AbMax Biotechnology. The biological activity of c7D3 was studied. The results showed that c7D3 exhibited high affinity for TIGIT and effectively inhibited the interaction between TIGIT and its ligands. Cell-based assays indicated that c7D3 induced strong luciferase signaling in TIGIT/CD155 signaling reporter assay and enhanced cytokine secretion in a T cell stimulation assay. The data showed that c7D3 has high binding affinity and excellent blocking bioactivity, supporting the further advancement for therapeutic application.
, correspAuthors=Hai-bin WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=Copyright ©2022 Acta Pharmaceutica Sinica. All rights reserved., copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Zhen-hua WU, Na LI, Juan CHEN, Mei-zhu JIANG, Yao CHEN, Xiao-fen MEI, Hai-bin WANG), CN=ArticleExt(id=1210517370691514405, articleId=1210517367105385436, tenantId=1146029695717560320, journalId=1189982191388893191, language=CN, title=抗TIGIT单克隆抗体的制备及体外生物学活性的初步研究, columnId=1190335348896011050, journalTitle=药学学报, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
T细胞免疫球蛋白和ITIM结构域蛋白(TIGIT) 通过多种机制抑制固有和适应性免疫, 是肿瘤免疫治疗的新型靶点。本研究利用重组人源TIGIT胞外区蛋白免疫BALB/c小鼠(本研究中的小鼠按照国际实验动物护理和使用准则进行使用, 并经委托单位京天成生物技术(北京) 有限公司实验动物伦理委员会批准), 分离并提取小鼠脾淋巴细胞常规融合, 成功筛选得到抗TIGIT单克隆抗体c7D3, 并初步研究了其生物学活性。结果表明, 抗体c7D3能高亲和地结合TIGIT, 并能有效阻断TIGIT与配体的结合。细胞功能实验证实, c7D3能激活T细胞, 在TIGIT/CD155报告基因实验中促进荧光素酶表达, 提高人外周血单个核细胞分泌细胞因子的能力。本研究表明, 抗体c7D3具有高亲和力和良好的生物学活性, 有望开发成为新的肿瘤免疫治疗的抗体药物。
, correspAuthors=王海彬, authorNote=null, correspAuthorsNote=
, copyrightStatement=版权所有©《药学学报》编辑部2022, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=fl2YUH3VdFMvUDTuyNyFvA==, magXml=iCDecyOwq6cpXNh9Fi7ZgQ==, pdfUrl=null, pdf=EASkVFjtiZQGJTnSSJtUsA==, pdfFileSize=1417344, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=xk12qujf6CkhIUsmZE3+2g==, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=vgIar55GQeLM7vaDspkwUQ==, mapNumber=null, authorCompany=null, fund=null, authors=
, authorsList=吴振华, 李娜, 陈娟, 蒋美珠, 陈瑶, 梅小芬, 王海彬)}, authors=[Author(id=1210517371039641666, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210517371127722058, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371039641666, language=EN, stringName=Zhen-hua WU, firstName=Zhen-hua, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210517371190636622, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371039641666, language=CN, stringName=吴振华, firstName=振华, middleName=null, lastName=吴, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
#, address=浙江博锐生物制药有限公司, 浙江 台州 318000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])]), Author(id=1210517371240968277, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210517371308077148, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371240968277, language=EN, stringName=Na LI, firstName=Na, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210517371446489186, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371240968277, language=CN, stringName=李娜, firstName=娜, middleName=null, lastName=李, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
#, address=浙江博锐生物制药有限公司, 浙江 台州 318000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])]), Author(id=1210517371559735401, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210517371652010095, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371559735401, language=EN, stringName=Juan CHEN, firstName=Juan, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210517371748479094, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371559735401, language=CN, stringName=陈娟, firstName=娟, middleName=null, lastName=陈, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=浙江博锐生物制药有限公司, 浙江 台州 318000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])]), Author(id=1210517371828170877, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210517371907862663, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371828170877, language=EN, stringName=Mei-zhu JIANG, firstName=Mei-zhu, middleName=null, lastName=JIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210517372008525964, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517371828170877, language=CN, stringName=蒋美珠, firstName=美珠, middleName=null, lastName=蒋, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=浙江博锐生物制药有限公司, 浙江 台州 318000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])]), Author(id=1210517372092412050, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210517372230824095, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517372092412050, language=EN, stringName=Yao CHEN, firstName=Yao, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210517372423762087, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517372092412050, language=CN, stringName=陈瑶, firstName=瑶, middleName=null, lastName=陈, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=浙江博锐生物制药有限公司, 浙江 台州 318000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])]), Author(id=1210517373619138737, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1210517373807882430, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517373619138737, language=EN, stringName=Xiao-fen MEI, firstName=Xiao-fen, middleName=null, lastName=MEI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210517373912740035, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517373619138737, language=CN, stringName=梅小芬, firstName=小芬, middleName=null, lastName=梅, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=浙江博锐生物制药有限公司, 浙江 台州 318000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])]), Author(id=1210517374000820426, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, orderNo=6, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=haibin.wang@bioraypharm.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1210517374118260947, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517374000820426, language=EN, stringName=Hai-bin WANG, firstName=Hai-bin, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
*, address=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1210517374193758425, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, authorId=1210517374000820426, language=CN, stringName=王海彬, firstName=海彬, middleName=null, lastName=王, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
*, address=浙江博锐生物制药有限公司, 浙江 台州 318000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])])], keywords=[Keyword(id=1210517374336364769, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, orderNo=1, keyword=TIGIT), Keyword(id=1210517374411862249, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, orderNo=2, keyword=hybridoma), Keyword(id=1210517374546079986, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, orderNo=3, keyword=monoclonal antibody), Keyword(id=1210517374638354679, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, orderNo=4, keyword=chimeric antibody), Keyword(id=1210517374734823682, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, orderNo=5, keyword=bioactivity), Keyword(id=1210517374831292681, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, orderNo=1, keyword=TIGIT), Keyword(id=1210517374957121808, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, orderNo=2, keyword=杂交瘤), Keyword(id=1210517375053590808, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, orderNo=3, keyword=单克隆抗体), Keyword(id=1210517375179419936, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, orderNo=4, keyword=嵌合抗体), Keyword(id=1210517375284277547, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, orderNo=5, keyword=生物学活性)], refs=[Reference(id=1210517376722923911, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=null, pmid=null, pmcid=null, year=2020, volume=55, issue=null, pageStart=1110, pageEnd=1118, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=Acta Pharm Sin (药学学报), refType=null, unstructuredReference=Shao RG. Monoclonal antibody-based cancer immunotherapy[J].
Acta Pharm Sin (药学学报),
2020,
55: 1110-1118., articleTitle=Monoclonal antibody-based cancer immunotherapy, refAbstract=null), Reference(id=1210517376848753039, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1016/j.febslet.2013.10.015, pmid=null, pmcid=null, year=2014, volume=588, issue=null, pageStart=368, pageEnd=376, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=FEBS Lett, refType=null, unstructuredReference=Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy[J].
FEBS Lett,
2014,
588: 368-376., articleTitle=Checkpoint blocking antibodies in cancer immunotherapy, refAbstract=null), Reference(id=1210517378048323996, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1158/1078-0432.CCR-15-1849, pmid=null, pmcid=null, year=2016, volume=22, issue=null, pageStart=1856, pageEnd=1864, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=Clin Cancer Res, refType=null, unstructuredReference=Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer[J].
Clin Cancer Res,
2016,
22: 1856-1864., articleTitle=Reversing T-cell dysfunction and exhaustion in cancer, refAbstract=null), Reference(id=1210517378195124644, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1158/2326-6066.CIR-18-0214, pmid=null, pmcid=null, year=2018, volume=6, issue=null, pageStart=1122, pageEnd=1128, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=Cancer Immunol Res, refType=null, unstructuredReference=Tray N, Weber JS, Adams S. Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application[J].
Cancer Immunol Res,
2018,
6: 1122-1128., articleTitle=Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application, refAbstract=null), Reference(id=1210517378333536684, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1158/2326-6066.CIR-19-0148, pmid=null, pmcid=null, year=2019, volume=7, issue=null, pageStart=1224, pageEnd=1229, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=Cancer Immunol Res, refType=null, unstructuredReference=Lesokhin AM, Bal S, Badros AZ. Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma[J].
Cancer Immunol Res,
2019,
7: 1224-1229., articleTitle=Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma, refAbstract=null), Reference(id=1210517378413228467, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1002/eji.200839116, pmid=null, pmcid=null, year=2009, volume=39, issue=null, pageStart=695, pageEnd=703, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=Eur J Immunol, refType=null, unstructuredReference=Boles KS, Vermi W, Facchetti F, et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC[J].
Eur J Immunol,
2009,
39: 695-703., articleTitle=A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC, refAbstract=null), Reference(id=1210517378518086075, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1016/j.it.2016.10.002, pmid=null, pmcid=null, year=2017, volume=38, issue=null, pageStart=20, pageEnd=28, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=Trends Immunol, refType=null, unstructuredReference=Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle[J].
Trends Immunol,
2017,
38: 20-28., articleTitle=TIGIT: a key inhibitor of the cancer immunity cycle, refAbstract=null), Reference(id=1210517378669081028, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1111/cei.13407, pmid=null, pmcid=null, year=2020, volume=200, issue=null, pageStart=108, pageEnd=119, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=Clin Exp Immunol, refType=null, unstructuredReference=Harjunpaa H, Guillerey C. TIGIT as an emerging immune checkpoint[J].
Clin Exp Immunol,
2020,
200: 108-119., articleTitle=TIGIT as an emerging immune checkpoint, refAbstract=null), Reference(id=1210517378769744330, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1007/s00335-018-9770-7, pmid=null, pmcid=null, year=2018, volume=29, issue=null, pageStart=694, pageEnd=702, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=Mamm Genome, refType=null, unstructuredReference=Stamm H, Wellbrock J, Fiedler W. Interaction of PVR/PVRL2 with TIGIT /DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer[J].
Mamm Genome,
2018,
29: 694-702., articleTitle=Interaction of PVR/PVRL2 with TIGIT /DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer, refAbstract=null), Reference(id=1210517378979459537, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1038/ni.1674, pmid=null, pmcid=null, year=2009, volume=10, issue=null, pageStart=48, pageEnd=57, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=Nat Immunol, refType=null, unstructuredReference=Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells[J].
Nat Immunol,
2009,
10: 48-57., articleTitle=The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells, refAbstract=null), Reference(id=1210517379096900060, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.4049/jimmunol.1003081, pmid=null, pmcid=null, year=2011, volume=186, issue=null, pageStart=1338, pageEnd=1342, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=J Immunol, refType=null, unstructuredReference=Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions[J].
J Immunol,
2011,
186: 1338-1342., articleTitle=Cutting edge: TIGIT has T cell-intrinsic inhibitory functions, refAbstract=null), Reference(id=1210517379176591839, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.4049/jimmunol.1103627, pmid=null, pmcid=null, year=2012, volume=188, issue=null, pageStart=3869, pageEnd=3875, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=J Immunol, refType=null, unstructuredReference=Ester L, Margarita DV, Vijay K, et al. The TIGIT/CD226 axis regulates human T cell function[J].
J Immunol,
2012,
188: 3869-3875., articleTitle=The TIGIT/CD226 axis regulates human T cell function, refAbstract=null), Reference(id=1210517379281449449, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1038/cdd.2012.141, pmid=null, pmcid=null, year=2013, volume=20, issue=null, pageStart=456, pageEnd=464, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=Cell Death Differ, refType=null, unstructuredReference=Liu S, Zhang H, Li M, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells[J].
Cell Death Differ,
2013,
20: 456-464., articleTitle=Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells, refAbstract=null), Reference(id=1210517379436638704, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1038/s41590-018-0132-0, pmid=null, pmcid=null, year=2018, volume=19, issue=null, pageStart=723, pageEnd=732, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=Nat Immunol, refType=null, unstructuredReference=Zhang Q, Bi JC, Zheng XD, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity[J].
Nat Immunol,
2018,
19: 723-732., articleTitle=Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity, refAbstract=null), Reference(id=1210517379579245052, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=null, pmid=null, pmcid=null, year=2018, volume=132, issue=null, pageStart=1689, pageEnd=1694, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=Blood, refType=null, unstructuredReference=Guillerey C, Harjunpää H, Carrié N, et al. TIGIT immune checkpoint blockade restores CD8
+ T cell immunity against multiple myeloma[J].
Blood,
2018,
132: 1689-1694., articleTitle=TIGIT immune checkpoint blockade restores CD8
+ T cell immunity against multiple myeloma, refAbstract=null), Reference(id=1210517379679908352, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1172/jci.insight.121157, pmid=null, pmcid=null, year=2018, volume=3, issue=null, pageStart=e121157, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=JCI Insight, refType=null, unstructuredReference=Fourcade J, Sun ZJ, Chauvin JM, et al. CD226 opposes TIGIT to disrupt Tregs in melanoma[J].
JCI Insight,
2018,
3: e121157., articleTitle=CD226 opposes TIGIT to disrupt Tregs in melanoma, refAbstract=null), Reference(id=1210517379784765960, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1158/2326-6066.CIR-18-0725, pmid=null, pmcid=null, year=2019, volume=7, issue=null, pageStart=1700, pageEnd=1713, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=Cancer Immunol Res, refType=null, unstructuredReference=Wu L, Mao L, Liu JF, et al. Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability[J].
Cancer Immunol Res,
2019,
7: 1700-1713., articleTitle=Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability, refAbstract=null), Reference(id=1210517379931566607, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.3390/ph14030200, pmid=null, pmcid=null, year=2021, volume=14, issue=null, pageStart=200, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=Pharmaceuticals (Basel), refType=null, unstructuredReference=Yeo J, Ko M, Lee DH, et al. TIGIT/CD226 axis regulates anti-tumor immunity[J].
Pharmaceuticals (Basel),
2021,
14: 200., articleTitle=TIGIT/CD226 axis regulates anti-tumor immunity, refAbstract=null), Reference(id=1210517380036424213, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1073/pnas.0903474106, pmid=null, pmcid=null, year=2009, volume=106, issue=null, pageStart=17858, pageEnd=17863, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=Proc Natl Acad Sci U S A, refType=null, unstructuredReference=Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity[J].
Proc Natl Acad Sci U S A,
2009,
106: 17858-17863., articleTitle=The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity, refAbstract=null), Reference(id=1210517380191613469, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1158/0008-5472.CAN-17-0381, pmid=null, pmcid=null, year=2017, volume=77, issue=null, pageStart=6375, pageEnd=6388, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=Cancer Res, refType=null, unstructuredReference=He W, Zhang H, Han F, et al. CD155T/TIGIT signaling regulates CD8
+ T-cell metabolism and promotes tumor progression in human gastric cancer[J].
Cancer Res,
2017,
77: 6375-6388., articleTitle=CD155T/TIGIT signaling regulates CD8
+ T-cell metabolism and promotes tumor progression in human gastric cancer, refAbstract=null), Reference(id=1210517380304859682, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1136/jitc-2020-000957, pmid=null, pmcid=null, year=2020, volume=8, issue=null, pageStart=e000957, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=J Immunother Cancer, refType=null, unstructuredReference=Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy[J].
J Immunother Cancer,
2020,
8: e000957., articleTitle=TIGIT in cancer immunotherapy, refAbstract=null), Reference(id=1210517380489409065, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1080/2162402X.2021.1873607, pmid=null, pmcid=null, year=2021, volume=10, issue=null, pageStart=1873607, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=Oncoimmunology, refType=null, unstructuredReference=Martinez M, Kim S, Jean NS, et al. Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer[J].
Oncoimmunology,
2021,
10: 1873607., articleTitle=Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer, refAbstract=null), Reference(id=1210517380573295155, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1172/JCI80445, pmid=null, pmcid=null, year=2015, volume=125, issue=null, pageStart=2046, pageEnd=2058, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=J Clin Invest, refType=null, unstructuredReference=Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients[J].
J Clin Invest,
2015,
125: 2046-2058., articleTitle=TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients, refAbstract=null), Reference(id=1210517380652986939, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1016/j.apsb.2021.09.011, pmid=null, pmcid=null, year=2021, volume=11, issue=null, pageStart=3925, pageEnd=3934, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=Acta Pharm Sin B, refType=null, unstructuredReference=Fu ZH, Liu HC, Wang L, et al. A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT[J].
Acta Pharm Sin B,
2021,
11: 3925-3934., articleTitle=A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT, refAbstract=null), Reference(id=1210517380741067332, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.3389/fimmu.2021.699895, pmid=null, pmcid=null, year=2021, volume=12, issue=null, pageStart=699895, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=Front Immunol, refType=null, unstructuredReference=Ge ZH, Peppelenbsch MP, Sprengers D, et al. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer[J].
Front Immunol,
2021,
12: 699895., articleTitle=TIGIT, the next step towards successful combination immune checkpoint therapy in cancer, refAbstract=null), Reference(id=1210517380862702152, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=null, pmid=null, pmcid=null, year=2020, volume=38, issue=null, pageStart=9503, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=J Chin Oncol, refType=null, unstructuredReference=Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase Ⅱ study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo)
versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)[J].
J Chin Oncol,
2020,
38: 9503., articleTitle=Primary analysis of a randomized, double-blind, phase Ⅱ study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo)
versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE), refAbstract=null), Reference(id=1210517380963365456, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.1016/j.annonc.2021.11.002, pmid=null, pmcid=null, year=2022, volume=33, issue=null, pageStart=169, pageEnd=180, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=Ann Oncol, refType=null, unstructuredReference=Niu J, Maurice D, Lee DH, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer[J].
Ann Oncol,
2022,
33: 169-180., articleTitle=First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer, refAbstract=null), Reference(id=1210517381064028760, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, doi=10.3389/fimmu.2022.828319, pmid=null, pmcid=null, year=2022, volume=13, issue=null, pageStart=828319, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=Front Immunol, refType=null, unstructuredReference=Chen X, Xue L, Ding X, et al. An Fc-competent anti-human TIGIT blocking antibody ociperlimab (BGBA1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models[J].
Front Immunol,
2022,
13: 828319., articleTitle=An Fc-competent anti-human TIGIT blocking antibody ociperlimab (BGBA1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1210517370888646709, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, xref=null, ext=[AuthorCompanyExt(id=1210517370897035319, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=BioRay Pharmaceutical Co., Ltd., Taizhou 318000, China), AuthorCompanyExt(id=1210517370901229624, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, companyId=1210517370888646709, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=浙江博锐生物制药有限公司, 浙江 台州 318000)])], figs=[ArticleFig(id=1210517375540130103, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, label=null, caption=null, figureFileSmall=5sEU3405B2nOtBXLKdVUlg==, figureFileBig=xk12qujf6CkhIUsmZE3+2g==, tableContent=null), ArticleFig(id=1210517375619821887, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, label=Figure 1, caption=
The binding activity of hybridoma supernatants to TIGIT (A) and the blocking activity towards TIGIT/CD155 interaction (B) were determined by ELISA. TIGIT: T cell immune receptor with Ig and ITIM domains , figureFileSmall=5sEU3405B2nOtBXLKdVUlg==, figureFileBig=xk12qujf6CkhIUsmZE3+2g==, tableContent=null), ArticleFig(id=1210517375842120009, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, label=null, caption=null, figureFileSmall=MFccDHTTX/lQAFE9QvAkVA==, figureFileBig=BIYKFqJIRmG/TfM6E3ggYA==, tableContent=null), ArticleFig(id=1210517375967949136, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, label=Figure 2, caption=
Purity analysis of antibody c7D3 by SDS-PAGE (A) and SEC-HPLC (B). M: Protein marker (kDa); Lane 1: c7D3 under reducing condition , figureFileSmall=MFccDHTTX/lQAFE9QvAkVA==, figureFileBig=BIYKFqJIRmG/TfM6E3ggYA==, tableContent=null), ArticleFig(id=1210517376077001047, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, label=null, caption=null, figureFileSmall=qBApwIz06SMkEqpkCaU+nQ==, figureFileBig=UrcTiU1NbZ9VL0+CuNfvgQ==, tableContent=null), ArticleFig(id=1210517376177664351, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, label=Figure 3, caption=
The binding activities of c7D3. A: Analysis of TIGIT expression in 293T-TIGIT cell line by flow cytometry; B: Binding to recombinant TIGIT was analyzed by ELISA; C: Binding to 293T-TIGIT cell line was analyzed by flow cytometry. <i>n</i> = 3, mean ± SEM , figureFileSmall=qBApwIz06SMkEqpkCaU+nQ==, figureFileBig=UrcTiU1NbZ9VL0+CuNfvgQ==, tableContent=null), ArticleFig(id=1210517376286716261, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, label=null, caption=null, figureFileSmall=mUf7Cz51I/QUrwbl/b+CPw==, figureFileBig=MHrrydzVVcREGUiJARxBbw==, tableContent=null), ArticleFig(id=1210517376408351088, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, label=Figure 4, caption=
The blocking activities of c7D3 towards TIGIT/CD155 interaction (A) and TIGIT/CD112 interaction (B) were determined by competition inhibition ELISA. <i>n</i> = 3, mean ± SEM , figureFileSmall=mUf7Cz51I/QUrwbl/b+CPw==, figureFileBig=MHrrydzVVcREGUiJARxBbw==, tableContent=null), ArticleFig(id=1210517376509014391, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=EN, label=null, caption=null, figureFileSmall=eHFzvu+bYbO1LtGzBasQyg==, figureFileBig=FaxaJ23kiiOP7E06DJ6EKA==, tableContent=null), ArticleFig(id=1210517376626454909, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1210517367105385436, language=CN, label=Figure 5, caption=
Functional assay of c7D3. A: The effect of c7D3 in a TIGIT/CD155 signaling reporter assay. Data represent a representative experiment; B: The effect of c7D3 and/or anti-PD-L1 mAb on IL-2 production; C: The effect of c7D3 and/or anti-PD-L1 mAb on IFN-<i>γ</i> production. PD-L1: Programmed cell death ligand 1; mAb: Monoclonal antibody; IL-2: Interleukin 2; IFN-<i>γ</i>: Interferon gamma. <i>n</i> = 3, mean ± SEM. <sup>*</sup><i>P</i> < 0.05, <sup>**</sup> <i>P</i> < 0.01, <sup>***</sup> <i>P</i> < 0.001 <i>vs</i> respective isotype control group (IgG1). ns: No significance , figureFileSmall=eHFzvu+bYbO1LtGzBasQyg==, figureFileBig=FaxaJ23kiiOP7E06DJ6EKA==, tableContent=null)], attaches=null, journal=Journal(id=1189982048455397383, delFlag=0, nameCn=药学学报, nameEn=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, issn=0513-4870, eissn=null, cn=11-2163/R, coden=null, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=BTxjudbJDVO4PqdBR6On6Q==, journalPrice=null, startedYear=null, abbrevIsoEn=null, journalRemark=null, publicationField=null, createdTime=1761643429151, updatedTime=1761735768113, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=A, firstLetterEn=A, subjectCode=Life Sciences, subjectName=Life Sciences, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=BTxjudbJDVO4PqdBR6On6Q==, picEn=c4l1ckL55nWbhl1KrFdWIA==, jcr=null, cjcr=null, exts=[JournalExt(id=1190369346338783397, language=CN, name=药学学报, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735768160, updatedTime=1761735768160, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1190369346376532134, language=EN, name=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735768169, updatedTime=1761735768169, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1189982191388893191, websiteList=[Website(id=1189982271588340489, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/CN, language=CN, createTime=1761643482348, createBy=18614031015, updateTime=1761643498101, updateBy=18614031015, name=药学学报-中文, tplId=1146099689490845704, title=药学学报, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982873114448678, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=articleTextType, value=kx, createTime=1761643625763, updateTime=1761643625763, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873093477155, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=banner, value=null, createTime=1761643625758, updateTime=1761643625758, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873135420201, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=grayFlag, value=0, createTime=1761643625768, updateTime=1761643625768, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873085088546, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643625756, updateTime=1761643625756, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873152197419, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=minRunFlag, value=0, createTime=1761643625772, updateTime=1761643625772, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873110254373, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic, createTime=1761643625762, updateTime=1761643625762, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873143808810, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=silenceFlag, value=0, createTime=1761643625770, updateTime=1761643625770, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873101865764, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1761643625760, updateTime=1761643625760, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873122837287, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeColor, value=null, createTime=1761643625765, updateTime=1761643625765, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873127031592, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeStyle, value=null, createTime=1761643625766, updateTime=1761643625766, creator=18614031015, updator=18614031015)]), Website(id=1189982271655449355, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/EN, language=EN, createTime=1761643482364, createBy=18614031015, updateTime=1761643514085, updateBy=18614031015, name=药学学报-英文, tplId=1146101810881728533, title=Acta Pharmaceutica Sinica, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982903015633534, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=articleTextType, value=kx, createTime=1761643632892, updateTime=1761643632892, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902990467707, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=banner, value=null, createTime=1761643632886, updateTime=1761643632886, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903036605057, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=grayFlag, value=0, createTime=1761643632897, updateTime=1761643632897, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902982079098, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643632884, updateTime=1761643632884, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903053382275, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=minRunFlag, value=0, createTime=1761643632901, updateTime=1761643632901, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903007244925, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic, createTime=1761643632890, updateTime=1761643632890, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903044993666, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=silenceFlag, value=0, createTime=1761643632899, updateTime=1761643632899, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902998856316, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1761643632888, updateTime=1761643632888, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903019827839, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeColor, value=null, createTime=1761643632893, updateTime=1761643632893, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903028216448, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeStyle, value=null, createTime=1761643632895, updateTime=1761643632895, creator=18614031015, updator=18614031015)])], journalTitle=药学学报, weixinUrl=null, journalUrl=https://www.yxxb.com.cn/aps, iacademicId=null, status=1, seqNo=null, journalTitleEn=Acta Pharmaceutica Sinica, journalPhotoCn=BTxjudbJDVO4PqdBR6On6Q==, journalPhotoEn=c4l1ckL55nWbhl1KrFdWIA==, journalFirstLetter=A, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/10.16438/j.0513-4870.2022-0121, detailUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0121, pdfUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/PDF/10.16438/j.0513-4870.2022-0121, pdfUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/PDF/10.16438/j.0513-4870.2022-0121, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)
全屏
文章导航
PDF下载
171
71
关闭全屏
北京市海淀区学院南路86号
010-62199257
qkjq@cast.org.cn
